Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Axitinib in Advanced RCC
NCT04958473Phase 2Unknown
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in renal cell carcinoma (RCC), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Overall Response Rate at 12 months. Status: unknown.
02
Drugs
sintilimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04958473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958473.